Published by Josh White on 17th April 2024
(Sharecast News) - GSK unveiled encouraging outcomes from a pivotal phase three trial on Wednesday, on the potential of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea (GC), amid escalating resistance to current therapies.
URL: http://www.digitallook.com/dl/news/story/34227106/...